CLDN18.2 biomarkers
Elevation Oncology Narrows EO-3021 Trial to Claudin 18.2-Expressing Patients, Launches Combo Cohorts
The firm is using immunohistochemistry to gauge biomarker expression before enrolling patients in a trial of its CLDN 18.2-directed antibody-drug conjugate.
I-Mab Streamlines Operations, Focuses Pipeline on CLDN18.2-Directed Therapy
The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.
Carsgen to Seek Approval in China for Satri-Cel in Claudin18.2-Expressing Gastric Cancer
The firm said the Phase III trial met its primary endpoint of improvement in progression-free survival.
Alentis Therapeutics Raises $181.4M in Series D Financing
The firm plans to put the funds toward advancing its CLDN-1-directed antibody-drug conjugates, ALE.P02 and ALE.P03, into the clinic.
FDA Approves Astellas' Vyloy, Chemo in First-Line CLDN18.2-Positive Gastric Cancer With Roche CDx
Vyloy is the first CLDN18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.